Comparing methotrexate and tofacitinib for plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This study compares two medications, methotrexate and tofacitinib, to see which works better for chronic plaque psoriasis in adults with moderate to severe symptoms. If you've tried creams that didn't help enough, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 70 years, male or female, with moderate to severe plaque psoriasis
- Psoriasis has been present for at least 6 months and covers a significant area (PASI score > 10)
- Previous cream or ointment treatment for at least 4 weeks did not work well enough
- No other type of psoriasis or other skin condition that could interfere with the study
- No use of systemic or biologic psoriasis medications in the last 4 weeks, or topical treatments in the last 2 weeks
- Not allergic to methotrexate or tofacitinib, and no serious liver, kidney, blood, stomach, or immune system disorders or history of alcohol abuse
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
This study tests whether combining two medicines—methotrexate and tofacitinib—works better for people with a specific type of rheumatoid arthritis. It may be a good fit if you have moderate to severe arthritis, have had a joint biopsy that shows a certain cell pattern, and haven't used similar treatments before.
This study compares two oral medications, tofacitinib and upadacitinib, when added to methotrexate for people with rheumatoid arthritis. The goal is to see which one works better and is safer for controlling symptoms.
This study compares two existing medicines — tofacitinib and methotrexate — to see which one is better at treating severe alopecia areata, a condition that causes patchy or total hair loss. If you have severe hair loss, this trial might help you find an effective treatment.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
Hear when a new Chronic Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.